Literature DB >> 11561798

Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony.

J B Jonas, J K Hayler, S Panda-Jonas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11561798     DOI： 10.1007/s004170100293

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  J Glaucoma       Date:  2001-08       Impact factor: 2.503

2.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

3.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy.

Authors:  J B Jonas; J K Hayler; S Panda-Jonas
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

4.  Treatment of intraocular proliferations with intravitreal steroids.

Authors:  R Machemer; G Sugita; Y Tano
Journal:  Trans Am Ophthalmol Soc       Date:  1979

5.  Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.

Authors:  J K Challa; M C Gillies; P L Penfold; J F Gyory; A B Hunyor; F A Billson
Journal:  Aust N Z J Ophthalmol       Date:  1998-11
  5 in total
  8 in total

1.  Intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  J B Jonas; I Kreissig; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.

Authors:  A P Ciardella; J Klancnik; W Schiff; G Barile; K Langton; S Chang
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

3.  Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

4.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; P Hugger; G Sauder; S Panda-Jonas; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

5.  Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye.

Authors:  B R Kosobucki; W R Freeman; L Cheng
Journal:  Br J Ophthalmol       Date:  2006-03-10       Impact factor: 4.638

6.  Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study.

Authors:  J B Jonas; I Akkoyun; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

Review 7.  [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].

Authors:  J B Jonas; I Kreissig; B Kamppeter; R F Degenring
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

8.  Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study.

Authors:  Tamer A Macky; Dina Helmy; Nihal El Shazly
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-17       Impact factor: 3.535
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.